ECOR: 1Q:21 Results msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
6 April 2021
The MHRA is committed to speeding up access to innovative new medicines for patients. The Early Access to Medicines Scheme (EAMS) gives patients with life threatening or seriously debilitating conditions access to medicines that do not yet have a marketing authorisation when there is a clear unmet medical need. The scheme has remained fully operational throughout the coronavirus (COVID-19) pandemic, ensuring that patients with serious conditions can still be offered new treatment options for their conditions.
As an example, the MHRA issued a positive scientific opinion for Roche’s atezolizumab (Tecentriq) in a new combination regimen for patients with unresectable hepatocellular carcinoma (HCC) in June 2020. Atezolizumab is a monoclonal antibody that directly binds programmed death-ligand 1 (PD-L1). PD-L1 may be expressed on tumour cells and/or tumour-infiltrating-immune cells and can contribute to the inhibition of the anti-tumour immune response in the tumour micro
Oldham News | Main News | Pregnant women benefit from rapid testing and digital remote monitoring for pre-eclampsia during COVID-19 oldham-chronicle.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from oldham-chronicle.co.uk Daily Mail and Mail on Sunday newspapers.
Increased access to Mavenclad (cladribine tablets) for Multiple Sclerosis patients in Response to the COVID-19 Pandemic NHS England responds to the COVID-19 pandemic by simplifying eligibility requirements for patients with highly active relapsing MS starting cladribine tabletsAmends made to Blueteq form suspen.
Patients with diabetes and high blood pressure are benefiting from pioneering artificial intelligence (AI) that turns a smartphone camera into a clinical-grade tool to detect early kidney disease.